Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02665234 · ClinicalTrials.gov registry record · Phase 3
A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease
A Phase 3 study of Keratoconjunctivitis Sicca, sponsored by Mimetogen Pharmaceuticals USA.
- Completed
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 1
- Study location
NCT02665234 is a Phase 3 study of Keratoconjunctivitis Sicca that has completed, run by Mimetogen Pharmaceuticals USA. The registered enrollment target is 400 participants, above the 128-participant average among 9 other Keratoconjunctivitis Sicca trials with a reported enrollment target (213% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02665234, a Phase 3 study of Keratoconjunctivitis Sicca, has completed, sponsored by Mimetogen Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the safety and efficacy of Tavilermide Ophthalmic Solution compared with Placebo Ophthalmic Solution in treating the signs and symptoms of dry eye disease.
Conditions Studied
Interventions
- DRUG Placebo Ophthalmic Solution
- DRUG 1% Tavilermide Ophthalmic Solution
Study Locations (1)
California
- MIM-726 Investigational Site - Torrance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2016-01 |
| Est. Completion | 2017-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02665234
The ClinicalTrials.gov registry entry for NCT02665234 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 128-participant average among 9 other Keratoconjunctivitis Sicca trials with a reported enrollment target (213% higher). The listed sponsor is Mimetogen Pharmaceuticals USA, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Keratoconjunctivitis Sicca appearing as the primary indexed condition, and to 2 interventions - of which Placebo Ophthalmic Solution is the first listed.
NCT02665234 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02665234 about?
NCT02665234 is a clinical study titled "A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease". The purpose of this study is to assess the safety and efficacy of Tavilermide Ophthalmic Solution compared with Placebo Ophthalmic Solution in treating the signs and symptoms of dry eye disease.
What is the current status of trial NCT02665234?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2016-01. Estimated completion is 2017-03.
What conditions does trial NCT02665234 study?
This clinical trial studies the following conditions: Keratoconjunctivitis Sicca.
What interventions are being tested in trial NCT02665234?
The interventions under investigation include: Placebo Ophthalmic Solution (DRUG), 1% Tavilermide Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT02665234?
This trial is sponsored by Mimetogen Pharmaceuticals USA, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02665234 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Keratoconjunctivitis Sicca
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TearLab Core Validation Study to Establish Referent Values for Dry Eye Disease
COMPLETED
-
Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye
COMPLETED · Phase 2
-
Effects of Dry Eye Treatments on the Ocular Surface
COMPLETED · Phase 4
-
Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops
COMPLETED · Phase 2
-
A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)
COMPLETED · Phase 1
-
Dry Eye Assessment and Management: Feasibility Study
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.